Nine-month results from FORECAST trial show statistically significant reduction in unnecessary invasive cardiac testing, increase in catheterization lab efficiency, and reduction in repeat non-invasive testing REDWOOD CITY, Calif.–(BUSINESS WIRE)–Late-breaking results presented today confirm that incorporating the HeartFlow® FFRct Analysis into a coronary computed tomography angiogram (CTA)-led diagnostic pathway significantly increases overall […]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–HeartFlow, Inc. today announced that it has obtained clearance from the U.S. Food and Drug Administration (FDA) for the HeartFlow Planner, a non-invasive, real-time virtual modeling tool for coronary artery disease (CAD) intervention. The HeartFlow Planner will enable interventional cardiologists to virtually model clinical scenarios vessel-by-vessel, explore treatment strategies […]

MUNICH–(BUSINESS WIRE)–Late-breaking data published and presented today confirm that the non-invasive HeartFlow®FFRct Analysis enables physicians to effectively differentiate patients in need of coronary stenting or bypass surgery from those who can be managed with medications alone. The ADVANCE Registry was published in the European Heart Journal (EHJ) and the Aarhus University Hospital […]

HeartFlow Completes Series E Financing, Securing $240 Million Proceeds Will Support Commercialization of HeartFlow® FFRct Analysis, Continued Technology Innovation and Additional Clinical Studies REDWOOD CITY, Calif.–(BUSINESS WIRE)– HeartFlow. today announced the closing of its Series E financing, securing $240 million. The company will use the proceeds from this financing to ramp up commercial […]